Compare Stocks: TVTX, UTHR, GMAB, and BBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$79.86 -1.7%	$77.36	$46.81 ▼ $93.42	$15.61B	0.96	2.01 million shs	3.09 million shs
GMAB Genmab A/S	$31.94 +1.9%	$27.98	$23.14 ▼ $35.43	$19.92B	0.83	2.17 million shs	3.42 million shs
TVTX Travere Therapeutics	$62.14 +1.2%	$56.51	$17.05 ▼ $66.24	$5.86B	1.12	1.69 million shs	1.19 million shs
UTHR United Therapeutics	$499.73 -0.3%	$535.95	$302.19 ▼ $609.35	$21.43B	0.59	518,533 shs	472,927 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	0.00%	-5.47%	-0.55%	+20.76%	+58.52%
GMAB Genmab A/S	0.00%	+2.21%	+10.21%	+20.35%	+40.89%
TVTX Travere Therapeutics	0.00%	+1.34%	+12.41%	+45.90%	+244.27%
UTHR United Therapeutics	0.00%	-7.26%	-5.54%	-12.11%	+61.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$79.86 -1.7%	$77.36	$46.81 ▼ $93.42	$15.61B	0.96	2.01 million shs	3.09 million shs
GMAB Genmab A/S	$31.94 +1.9%	$27.98	$23.14 ▼ $35.43	$19.92B	0.83	2.17 million shs	3.42 million shs
TVTX Travere Therapeutics	$62.14 +1.2%	$56.51	$17.05 ▼ $66.24	$5.86B	1.12	1.69 million shs	1.19 million shs
UTHR United Therapeutics	$499.73 -0.3%	$535.95	$302.19 ▼ $609.35	$21.43B	0.59	518,533 shs	472,927 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	0.00%	-5.47%	-0.55%	+20.76%	+58.52%
GMAB Genmab A/S	0.00%	+2.21%	+10.21%	+20.35%	+40.89%
TVTX Travere Therapeutics	0.00%	+1.34%	+12.41%	+45.90%	+244.27%
UTHR United Therapeutics	0.00%	-7.26%	-5.54%	-12.11%	+61.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.83	Moderate Buy	$100.79	26.21% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	23.67% Upside
TVTX Travere Therapeutics	2.69	Moderate Buy	$61.67	-0.76% Downside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	29.27% Upside

Current Analyst Ratings Breakdown

Latest TVTX, UTHR, GMAB, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/12/2026	BBIO BridgeBio Pharma	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$102.00 ➝ $107.00
8/12/2026	BBIO BridgeBio Pharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $106.00
8/12/2026	BBIO BridgeBio Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$100.00 ➝ $111.00
8/11/2026	BBIO BridgeBio Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/11/2026	GMAB Genmab A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/11/2026	BBIO BridgeBio Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00
8/11/2026	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$101.00 ➝ $104.00
8/11/2026	BBIO BridgeBio Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$98.00 ➝ $97.00
8/11/2026	BBIO BridgeBio Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $110.00
8/11/2026	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$98.00 ➝ $102.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$502.08M	31.09	N/A	N/A	($12.81) per share	-6.23
GMAB Genmab A/S	$3.72B	5.35	$1.61 per share	19.84	$9.55 per share	3.34
TVTX Travere Therapeutics	$490.73M	11.94	$0.36 per share	171.60	$0.26 per share	239.00
UTHR United Therapeutics	$3.18B	6.73	$32.99 per share	15.15	$149.22 per share	3.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	25.15	19.72	1.90	19.08%	14.89%	7.73%	N/A
TVTX Travere Therapeutics	-$25.55M	-$0.46	N/A	23.63	N/A	-7.35%	-55.15%	-6.88%	10/29/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	17.88	16.84	1.69	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest TVTX, UTHR, GMAB, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.23	1.48
GMAB Genmab A/S	0.81	2.46	2.44
TVTX Travere Therapeutics	24.58	4.05	3.99
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
GMAB Genmab A/S	7.07%
TVTX Travere Therapeutics	N/A
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
GMAB Genmab A/S	1.54%
TVTX Travere Therapeutics	4.44%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	195.49 million	167.67 million	Optionable
GMAB Genmab A/S	3,029	623.53 million	613.93 million	Optionable
TVTX Travere Therapeutics	460	94.26 million	90.08 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

TVTX, UTHR, GMAB, and BBIO Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,892,785.00 in Stock

3 hours ago | americanbankingnews.com

Q4 EPS Forecast for United Therapeutics Lowered by Analyst

August 16 at 1:42 AM | americanbankingnews.com

HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

August 14 at 8:41 AM | marketbeat.com

Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 13 at 7:06 PM | marketbeat.com

United Therapeutics’s Q2 earnings call: Our top 5 analyst questions

August 12, 2026 | msn.com

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

August 12, 2026 | fool.com

Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry

August 12, 2026 | investors.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 11, 2026 | insidertrades.com

United Therapeutics (NASDAQ:UTHR) EVP Sells $4,291,515.00 in Stock

August 9, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,928,030.00 in Stock

August 9, 2026 | americanbankingnews.com

Royal Bank Of Canada Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $677.00

August 9, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Purchases 37,355 Shares of United Therapeutics Corporation $UTHR

August 9, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Sees Strong Trading Volume - Should You Buy?

August 7, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

August 7, 2026 | insidertrades.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,902,570.00 in Stock

August 7, 2026 | americanbankingnews.com

United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE

August 7, 2026 | marketbeat.com

How Investors May Respond To United Therapeutics (UTHR) EPS Strength And Ralinepag’s Phase 3 Milestone

August 6, 2026 | finance.yahoo.com

Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 6, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 6, 2026 | marketbeat.com

Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained

August 6, 2026 | tipranks.com

UTHR Q2 2026 deep dive: Product pipeline developments offset competitive pressures

August 6, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX, UTHR, GMAB, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$79.86 -1.35 (-1.66%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$80.05 +0.19 (+0.24%)

As of 08/14/2026 07:34 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Genmab A/S NASDAQ:GMAB

$31.94 +0.60 (+1.91%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$31.80 -0.15 (-0.45%)

As of 08/14/2026 07:53 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Travere Therapeutics NASDAQ:TVTX

$62.14 +0.71 (+1.16%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$61.31 -0.83 (-1.34%)

As of 08/14/2026 07:36 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

United Therapeutics NASDAQ:UTHR

$499.73 -1.54 (-0.31%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$499.92 +0.19 (+0.04%)

As of 08/14/2026 07:34 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVTX, UTHR, GMAB, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVTX, UTHR, GMAB, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVTX, UTHR, GMAB, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX, UTHR, GMAB, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Genmab A/S NASDAQ:GMAB

Travere Therapeutics NASDAQ:TVTX

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVTX, UTHR, GMAB, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVTX, UTHR, GMAB, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVTX, UTHR, GMAB, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX, UTHR, GMAB, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Genmab A/S NASDAQ:GMAB

Travere Therapeutics NASDAQ:TVTX

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools